Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.

ABSTRACT:

Background

Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy.

Aims

To enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early time point after starting therapy.

Methods

The clinical study data request website provided the phase 3 clinical trial data for vedolizumab. Random forest models were trained on 70% and tested on 30% of the data to predict corticosteroid-free endoscopic remission at week 52. Models were constructed using baseline data, or data through week 6 of vedolizumab therapy from 491 subjects.

Results

The AuROC for prediction of corticosteroid-free endoscopic remission at week 52 using bas

SUBMITTER: Waljee AK 

PROVIDER: S-EPMC5814341 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature